Sarcio has developed a proprietary platform technology that utilizes induced pluripotent stem cells (iPSCs) to grow cartilage tissue, creating a robust source of exosomes that carry regenerative signals to promote healing and repair in osteoarthritic joints. Exosomes are naturally occurring messengers released by cells that carry proteins, RNA, and signaling molecules. Our proprietary biologics utilize the signalling capabilities of these particles to target damaged tissues, modulate inflammation, and stimulate healing. Our platform enables a scalable and renewable manufacturing process. This approach enables consistent purity, potency, and therapeutic performance that are critical for both clinical translation and commercial success.
| Website | https://www.sarcioinc.com/ |
| Employees | 4 (2 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Cartilage Regeneration, Stem Cell Therapy, Regenerative Medicine, Osteoarthritis Treatment, Orthopedic Treatments, Inflammation Reduction, Cell Therapy, Tissue Regeneration, Joint Health, Orthopedics, Biotechnology, Medical Technology, Pharmaceutical, Clinical Trials, Drug Development, Health Technology, Life Sciences, Treatment |
| Competitors | Spectrum, Xfinity, AT&T, Verizon, Frontier Communications, Windstream Communications Telecom, Cox Communications, T-Mobile, DISH Network, Charter Network +39 more (view full list) |
Looking for a particular Sarcio Inc. employee's phone or email?
Beth Lindborg is the CEO of Sarcio Inc..
2 people are employed at Sarcio Inc..